Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

被引：2

作者：

Zhu, Viola Weijia

Bestvina, Christine M.

Lopes, Gilberto

Hamm, John Turner

Johnson, Melissa Lynne

Lammers, Philip Edward

Le, Xiuning

Marathe, Omkar

Raez, Luis E.

Rao, Suman

Sabari, Joshua K.

Scheff, Ronald J.

Tapan, Umit

Thompson, Jonathan Robert

Karachaliou, Niki

Ellers-Lenz, Barbara

Brutlach, Sabine

Smit, Egbert F.

Wu, Yi-Long

机构：

[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[4] Norton Canc Inst PARENT, Louisville, KY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Baptist Canc Ctr, Memphis, TN USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Innovat Clin Res Inst, Anaheim, CA USA

[9] Mem Healthcare Syst, Hollywood, FL USA

[10] Medstar Franklin Sq Clin Res Ctr, Baltimore, MD USA

[11] NYU Langone Clin Canc Ctr, New York, NY USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA

[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[15] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[16] Merck KGaA, Dept Biostat, Darmstadt, Germany

[17] Merck KGaA, Darmstadt, Germany

[18] Netherlands Canc Inst, Amsterdam, Netherlands

[19] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS9136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9136

引用

下载

页数：3

共 50 条

[31] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Zhou, Q.
Li, J.
Wang, J.
Yang, L.
Fang, J.
Dong, X.
Yi, T.
Min, X.
Xu, F.
Chen, J.
Zhong, D.
Bai, J.
Liu, L.
Zeng, A.
Tang, J.
Wu, H.
Luo, X.
Yu, J.
Su, W.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429
[32] Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
Choudhury, Noura J.
Marra, Antonio
Sui, Jane S. Y.
Flynn, Jessica
Yang, Soo-Ryum
Falcon, Christina J.
Selenica, Pier
Schoenfeld, Adam J.
Rekhtman, Natasha
Gomez, Daniel
Berger, Michael F.
Ladanyi, Marc
Arcila, Maria
Rudin, Charles M.
Riely, Gregory J.
Kris, Mark G.
Heller, Glenn
Reis-Filho, Jorge S.
Yu, Helena A.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 463 - 475
[33] Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
Wang, Kaiwen
Du, Robyn
Roy-Chowdhuri, Sinchita
Li, Ziping T.
Hong, Lingzhi
Vokes, Natalie
Elamin, Yasir Y.
Hume, Celyne Bueno
Skoulidis, Ferdinandos
Gay, Carl M.
Blumenschein, George
Fossella, Frank V.
Tsao, Anne
Zhang, Jianjun
Karachaliou, Niki
O'Brate, Aurora
Gann, Claudia-Nanette
Lewis, Jeff
Rinsurongkawong, Waree
Lee, J. Jack
Gibbons, Don Lynn
Vaporciyan, Ara A.
Heymach, John V.
Altan, Mehmet
Le, Xiuning
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
[34] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
Yu, Y.
Yang, N.
Zhang, Y.
Zhang, H.
Li, M.
Yu, Q.
Zhou, J.
Hu, X.
Fang, J.
Zhao, H.
Feng, J.
Li, L.
Shu, Y.
Wang, X.
Sun, M.
Zhang, J.
Li, M.
Ren, Y.
Lu, S.
ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
[35] Establishment and characterization of an EGFR-mutant NSCLC XPDX model representing first-line osimertinib resistance through an acquired TRIM24-BRAF fusion
Moriarty, A.
Flores, J.
Stackpole, A.
Ulmer, S.
Papadopoulos, K.
Patnaik, A.
Rasco, D.
Calvo, E.
Moreno, V.
Wick, M.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S111 - S111
[36] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
Wei, Fang
An, Juan
Hua, Yichun
Ding, Xiaosheng
Sun, Shibin
Li, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort
Piotrowska, Zofia
Chen, Lanyi Nora
Shum, Elaine
Park, Cathleen
Guo, Matthew
Liu, Ying
Tran, Misha
Marks, Jennifer Aline
Banwait, Mandeep
Liu, Stephen V.
Scott, Susan Combs
Bestvina, Christine M.
Riess, Jonathan W.
Marrone, Kristen A.
Hall, Richard Delmar
Gentzler, Ryan D.
Shu, Catherine A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
Choudhury, Noura J.
Marra, Antonio
Yang, Soo-Ryum
Falcon, Christina J.
Heller, Glenn
Kris, Mark G.
Reis-Filho, Jorge S.
Riely, Gregory J.
Yu, Helena Alexandra
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
Park, K.
Zhou, J.
Kim, D-W.
Ahmad, A. R.
Soo, R. A.
Bruns, R.
Straub, J.
Johne, A.
Scheele, J.
Yang, J. C-H.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2019, 30
[40] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
Oxnard, Geoffrey R.
Cantarini, Mireille
Frewer, Paul
Hawkins, George
Peters, Jane
Howarth, Paul
Ahmed, Ghada F.
Sahota, Tarjinder
Hartmaier, Ryan
Li-Sucholeiki, Xiaocheng
Ahn, Myung-Ju
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →